Series B · Consumer

TruNativ closes $30 million primary-and-secondary Series B with OrbiMed

The nutrition company will expand distribution, develop products and grow its ingredients business.

TruNativ announced a $30 million Series B transaction with OrbiMed on June 16. The deal combines new investment into the company with secondary share sales by early shareholders; the primary allocation was not disclosed.

The Mumbai nutrition business plans to expand distribution, broaden its product range and establish a research and innovation centre. It will also grow its ingredients business serving other consumer brands, alongside its household protein, fibre and sugar-alternative products.

Use of funds

Expand retail distribution

Develop nutrition products and R&D centre

Grow ingredients business

Funding history

Series B · This roundUndisclosed

Sources

  1. Nutrition brand TruNativ closes $30 million round with OrbiMed Advisors LLCeconomictimes.indiatimes.com · Jun 16, 2026